- Home
- PT vs KPRX Comparison
PT vs KPRX Comparison
Compare PT & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PT
- KPRX
- Stock Information
- Founded
- PT 2012
- KPRX 1998
- Country
- PT China
- KPRX United States
- Employees
- PT N/A
- KPRX N/A
- Industry
- PT Computer Software: Programming Data Processing
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PT Technology
- KPRX Health Care
- Exchange
- PT Nasdaq
- KPRX Nasdaq
- Market Cap
- PT 14.8M
- KPRX 12.0M
- IPO Year
- PT 2018
- KPRX N/A
- Fundamental
- Price
- PT $0.95
- KPRX $3.81
- Analyst Decision
- PT
- KPRX Strong Buy
- Analyst Count
- PT 0
- KPRX 1
- Target Price
- PT N/A
- KPRX $10.00
- AVG Volume (30 Days)
- PT 18.8K
- KPRX 42.1K
- Earning Date
- PT 11-08-2024
- KPRX 03-24-2025
- Dividend Yield
- PT N/A
- KPRX N/A
- EPS Growth
- PT N/A
- KPRX N/A
- EPS
- PT N/A
- KPRX 1.69
- Revenue
- PT $4,479,352.00
- KPRX $16,020,000.00
- Revenue This Year
- PT N/A
- KPRX N/A
- Revenue Next Year
- PT N/A
- KPRX N/A
- P/E Ratio
- PT N/A
- KPRX $2.25
- Revenue Growth
- PT N/A
- KPRX N/A
- 52 Week Low
- PT $0.71
- KPRX $3.00
- 52 Week High
- PT $1.27
- KPRX $7.65
- Technical
- Relative Strength Index (RSI)
- PT 47.63
- KPRX 54.01
- Support Level
- PT $0.93
- KPRX $3.50
- Resistance Level
- PT $1.01
- KPRX $4.14
- Average True Range (ATR)
- PT 0.07
- KPRX 0.25
- MACD
- PT -0.00
- KPRX 0.02
- Stochastic Oscillator
- PT 73.85
- KPRX 70.19
About PT Pintec Technology Holdings Limited
Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.